Here are five quick facts:
1. Oppenheimer set a $28 price target for Globus Medical shares.
2. Globus Medical currently has a “buy” rating.
3. There is a potential upside of 12.22 percent.
4. Globus Medical traded up 0.6 percent yesterday mid-day.
5. Market cap for the company is $2.36 million with a P/E ratio of 25.72.
Recently, WallachBeth Capital raised the price target on Globus to $30 from $26 and also gave the company a “buy” rating earlier this month. Leerink Swann also raised target price to $29 and gave the company an “outperform” rating, according to the report.
More articles on orthopedic devices:
Greatbatch short interest drops by 8.5% — 4 things to know
Amedica to present CASCADE clinical results
Spine device stock report: 5 key companies
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
